anti hiv medicine

Entewell 0.5mg Tablet: The Gold Standard for Chronic Hepatitis B Suppression – Global Supply by Ernest Oncology The long-term management of Chronic Hepatitis B (HBV) requires high-potency antiviral therapy with a high barrier to resistance. Entewell 0.5mg, containing the active ingredient Entecavir, is one of the most widely prescribed Nucleoside Analogs (NAs) globally. Designed for superior viral suppression, Entewell is a cornerstone in preventing the progression of liver disease, including cirrhosis and hepatocellular carcinoma. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Entewell 0.5mg to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Entewell 0.5mg? (The Entecavir Advantage) Entewell 0.5mg is a premium generic version of the world-renowned medication Baraclude. Entecavir is a potent guanosine nucleoside analog that selectively inhibits the Hepatitis B virus polymerase. Clinical data consistently shows that Entecavir is more effective than older treatments like Lamivudine, offering faster viral load reduction and a negligible rate of resistance in treatment-naive patients. Primary Indications & Medical Uses Chronic Hepatitis B Virus (HBV): For the treatment of chronic HBV infection in adults with evidence of active viral replication and persistent elevations in serum aminotransferases (ALT or AST). Compensated Liver Disease: Effective for patients with early-stage liver scarring to prevent further damage. HBeAg-Positive & HBeAg-Negative Patients: Proven efficacy across various viral profiles and stages of chronic infection. Nucleoside-Naive Patients: The preferred first-line therapy for patients who have not previously taken antiviral medications for HBV. Detailed Product Information: Entewell (0.5mg) Feature Technical Specification Active Ingredient Entecavir (0.5mg) Therapeutic Class Nucleoside Reverse Transcriptase Inhibitor (NRTI) Manufacturer Biocon / Natco Pharma (India) Form Film-coated tablets (30 Tablets per bottle) Treatment Type Long-term antiviral suppression Safety Profile High barrier to viral resistance Quality Standard GMP Certified Production Mechanism of Action: Triple-Stage Inhibition Entewell works by inhibiting the Hepatitis B virus polymerase at three distinct stages of its lifecycle: Base Priming: It prevents the initial attachment of the viral DNA. Reverse Transcription: It blocks the formation of the negative strand of the DNA from the pregenomic RNA. Dosage and Administration Standard Regimen: One 0.5mg tablet taken orally, once daily. Empty Stomach Rule: For optimal absorption, Entewell must be taken on an empty stomach (at least 2 hours after a meal and at least 2 hours before the next meal). Monitoring: Patients should undergo regular blood tests to monitor HBV DNA levels and liver enzymes to ensure treatment success. DNA Synthesis: It halts the synthesis of the positive strand of the viral DNA. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in the logistics of international pharmaceutical trade. We ensure that Entewell 0.5mg—manufactured in India’s leading biotech facilities—reaches our global partners through verified, temperature-controlled, and legal channels. United Kingdom & London: Supporting private hepatology clinics and specialized “Named Patient“ programs in London and nationwide. United States: Providing affordable access for clinical research, specialized pharmacy requirements, and hospital procurement. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s most advanced medical hubs and specialty clinics. Australia & South Africa: Reliable bulk supply for public health departments, regional medical distributors, and government tenders. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Mydekla Tablet: The Potent NS5A Inhibitor for Hepatitis C Eradication – Global Supply by Ernest Oncology The treatment of Chronic Hepatitis C (HCV) has been fundamentally transformed by the advent of Direct-Acting Antivirals (DAAs). Mydekla, containing Daclatasvir (60mg), is a cornerstone of this modern therapeutic approach. As a powerful NS5A inhibitor, Mydekla is designed to be used in combination with other antivirals to achieve high cure rates across multiple genotypes of the virus, offering a reliable path to viral clearance with an all-oral regimen. Ernest Oncology, the specialized pharmaceutical division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We ensure the secure, GMP-compliant international distribution of Mydekla to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Mydekla? (The Power of Daclatasvir) Mydekla is a high-quality generic version of the breakthrough medication Daklinza. It targets the Hepatitis C virus by inhibiting a specific protein the virus needs to replicate. When Mydekla is paired with a nucleotide analog like Sofosbuvir, it creates a robust antiviral shield that works effectively even in patients who have not responded to previous interferon-based treatments. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1, 3, & 4): Extensively used in combination with Sofosbuvir for these prevalent genotypes. HCV/HIV Co-infection: Highly recommended for patients managing both infections due to its minimal drug-drug interactions. Advanced Liver Disease: A vital treatment component for patients with compensated or decompensated cirrhosis. Post-Liver Transplant: Effective in managing HCV recurrence in liver transplant recipients. Detailed Product Information: Mydekla (60mg) Feature, Technical Specification Active Ingredient Daclatasvir (60mg) Therapeutic Class HCV NS5A Replication Complex Inhibitor Manufacturer Mylan (Viatris) / Natco Pharma (India) Form Film-coated tablets (28 Tablets per bottle) Treatment Cycle 12 to 24 Weeks (depending on regimen) Efficacy Rate >90% Sustained Virologic Response (SVR) Quality Standard GMP Certified Production Mechanism of Action: Blocking Viral Assembly Mydekla works by interfering with the most critical stage of the virus's lifecycle: Inhibiting NS5A Protein: Daclatasvir binds to the NS5A non-structural protein. This protein is essential for the replication of the viral RNA and the subsequent assembly of new virus particles. Halting the Viral Cycle: By blocking this protein, Mydekla ensures that the virus cannot reproduce or spread to healthy liver cells, allowing the body to clear the infection permanently. Dosage and Administration Standard Regimen: One 60mg tablet taken once daily. Combination Requirement: Mydekla must be taken in combination with other antiviral medicines (typically Sofosbuvir 400mg). Administration: Can be taken with or without food. It is essential to take the dose at the same time every day for maximum efficacy. Storage: Store in a cool, dry place below 30°C in the original moisture-proof container. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that Mydekla—manufactured in world-class Indian facilities—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology clinics and “Named Patient“ access programs throughout the UK. United States: Providing affordable access for specialized pharmacy requirements and clinical research. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s premier medical hubs and diagnostic centers. Australia & South Africa: Reliable bulk supply for public health initiatives and regional medical distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Myhep Tablet: The Gold Standard in Chronic Hepatitis C Treatment – Global Supply by Ernest Oncology The medical landscape for Chronic Hepatitis C (HCV) was forever changed with the introduction of Direct-Acting Antivirals (DAAs). Myhep, featuring the breakthrough active ingredient Sofosbuvir (400mg), remains the foundation of most successful HCV treatment regimens. As a potent nucleotide analog polymerase inhibitor, Myhep is designed to stop the virus at its source, offering a pathway to a permanent cure for millions worldwide. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Myhep to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Myhep? (The Sofosbuvir Breakthrough) Myhep is a high-quality generic version of the world-renowned medication Sovaldi. It contains Sofosbuvir (400mg), which was the first drug to offer high cure rates with a simplified oral regimen. Before Sofosbuvir, treatment often involved grueling interferon injections with low success rates; Myhep has replaced that era with an effective, all-oral solution. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1, 2, 3, & 4): Myhep is a versatile “backbone“ drug, usually used in combination with other antivirals (like Daclatasvir or Ledipasvir) to treat various HCV genotypes. HCV/HIV Co-infection: Proven safe for patients managing both conditions, maintaining a stable drug-interaction profile. Liver Transplant Candidates: Often used to prevent the recurrence of Hepatitis C in patients awaiting or recovering from a liver transplant. Detailed Product Information: Myhep (400mg) Feature, Technical Specification Active Ingredient, Sofosbuvir (400mg) Therapeutic Class Nucleotide Analog HCV NS5B Polymerase Inhibitor Manufacturer Mylan (Viatris) / Natco Pharma (India) Form, Film-coated tablets (28 Tablets per bottle) Standard Duration 12 to 24 Weeks (based on combination) Efficacy Rate >90% Sustained Virologic Response (SVR) Quality Standard GMP Certified Production Mechanism of Action: Chain Termination Myhep works by targeting the heart of the virus's replication machinery: NS5B Protein Inhibition: Sofosbuvir is a prodrug that, once inside the liver, converts into an active triphosphate. Stopping Replication: It mimics the natural building blocks of the virus's RNA. When the virus tries to use Myhep to build its genetic chain, the chain is “terminated,“ effectively stopping the virus from reproducing. Dosage and Administration Standard Regimen: One 400mg tablet taken once daily. Combination Therapy: Myhep is rarely used alone; it is typically taken with Ribavirin or another DAA (like Myhep DV). Administration: Can be taken with or without food. It is vital to take the tablet at the same time every day to ensure consistent antiviral levels. Storage: Store at room temperature (below 30°C) in its original moisture-proof container. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that Myhep—manufactured in world-class Indian facilities—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology clinics and “Named Patient“ access programs in London and nationwide. United States: Providing cost-effective supply for clinical research and specialized pharmacy networks. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s premier medical hubs and diagnostic centers. Australia & South Africa: Reliable bulk supply for public health initiatives and regional distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Daclahep Tablet: The Potent NS5A Inhibitor for Hepatitis C Cure – Global Supply by Ernest Oncology The evolution of Direct-Acting Antivirals (DAAs) has made Hepatitis C (HCV) a highly curable condition. Daclahep, containing Daclatasvir (60mg), is a cornerstone of modern HCV therapy. When used in combination with other antivirals like Sofosbuvir, it provides a robust, all-oral treatment pathway that targets the virus across multiple genotypes, ensuring high Sustained Virologic Response (SVR) rates. Ernest Oncology, the premier pharmaceutical division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We specialize in the secure, GMP-certified international distribution of Daclahep to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa. What is Daclahep? Daclahep is a high-quality generic version of the breakthrough medication Daklinza. As a powerful NS5A inhibitor, it prevents the Hepatitis C virus from replicating and assembling new viral particles. Because it is rarely used alone, it is most commonly paired with Sofosbuvir to create a pan-genotypic treatment regimen that eliminates the need for interferon injections. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1, 3, & 4): Particularly effective when combined with Sofosbuvir for these prevalent genotypes. Advanced Liver Disease: A vital component for patients with compensated or decompensated cirrhosis. Post-Liver Transplant: Used in specialized regimens to prevent HCV recurrence after transplantation. HCV/HIV Co-infection: Highly recommended for patients managing both infections due to its favorable drug-interaction profile. Detailed Product Information: Daclahep (60mg) Feature, Technical Specification Active Ingredient: Daclatasvir (60mg) Drug Class: NS5A Replication Complex Inhibitor Manufacturer: Hetero Healthcare / Natco Pharma (India) Form film-coated tablets (28 Tablets per pack) Standard Regimen, 12 to 24 Weeks (based on clinical profile) Quality Standard, GMP Certified Manufacturing Mechanism of Action: Disrupting Viral Assembly Daclahep works by targeting a specific protein within the Hepatitis C virus: NS5A Protein Inhibition: Daclatasvir binds to the NS5A non-structural protein. This protein is essential for both the replication of the viral RNA and the assembly of the new virus particles (virions). Viral Clearance: By blocking this protein, the medication stops the virus from spreading to new liver cells, allowing the body’s immune system and companion antivirals to clear the infection. Dosage and Administration Standard Dose: One 60mg tablet taken orally, once daily. Combination Therapy: Must be taken with Sofosbuvir (400mg) or as directed by a hepatologist. Administration: Can be taken with or without food. Consistency is vital—doses should be taken at the same time every day. Storage: Store in a cool, dry place below 30°C, protected from light and moisture. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in the complex logistics of international pharmaceutical trade. We ensure that Daclahep—manufactured by India's leading pharmaceutical giants—is delivered through verified, temperature-controlled, and legal channels. United Kingdom & London: Supporting private hepatology clinics and “Named Patient“ access programs in London and nationwide. United States: Providing cost-effective supply for clinical research and specialized pharmacy networks. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s premier medical hubs and diagnostic centers. Australia & South Africa: Reliable bulk supply for public health initiatives and regional distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of oncology and antiviral medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Hepcinat Plus Tablet: The Advanced Dual-Action Cure for Hepatitis C – Global Supply by Ernest Oncology The introduction of Direct-Acting Antiviral (DAA) combinations has revolutionized the treatment of Chronic Hepatitis C, turning a once-chronic condition into a curable one. Hepcinat Plus, a potent fixed-dose combination of Sofosbuvir (400mg) and Daclatasvir (60mg), stands at the forefront of this medical breakthrough. This combination is highly effective across multiple genotypes and is widely prescribed for its high cure rates and manageable side-effect profile. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Hepcinat Plus to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Hepcinat Plus? Hepcinat Plus is a high-quality generic version of the combination therapy used to treat Chronic Hepatitis C. By combining two distinct antiviral mechanisms, Hepcinat Plus eliminates the need for interferon injections, which were previously the standard of care but carried significant side effects. Clinical data indicates a Sustained Virologic Response (SVR12)—the clinical definition of a cure—in over 95% of treated patients. Primary Indications & Medical Uses Chronic Hepatitis C (Multiple Genotypes): Specifically effective for Genotypes 1, 3, and 4, providing a robust treatment path for a wide range of patients. HCV/HIV Co-infection: Safe for use in patients managing both Hepatitis C and HIV-1, with a well-documented drug-interaction profile. Patients with Cirrhosis: Effective for patients with compensated liver disease, often used to prevent further liver damage and the need for transplantation. Detailed Product Information: Hepcinat Plus (400mg/60mg) Feature, Technical Specification Active Ingredients: Sofosbuvir (400mg) + Daclatasvir (60mg) Drug Class: NS5B Polymerase Inhibitor + NS5A Inhibitor Manufacturer: Natco Pharma (India) Form: Film-coated tablets (28 Tablets per bottle) Treatment Duration, Standard 12-Week Course Success Rate: >95% Sustained Virologic Response (SVR) Quality Standard, GMP Certified Production Mechanism of Action: The Dual-Inhibitor Strategy Hepcinat Plus works by attacking the Hepatitis C virus at two critical stages of its replication cycle: Sofosbuvir (400mg): An NS5B polymerase inhibitor. It acts as a “chain terminator,“ preventing the virus from copying its genetic material (RNA). Daclatasvir (60mg): An NS5A inhibitor. It blocks the NS5A protein, which the virus requires for both the replication of the virus and the assembly of new viral particles. Dosage and Administration Standard Regimen: One tablet taken orally, once daily. Administration: Can be taken with or without food. Consistency is critical; the dose should be taken at the same time every day to maintain optimal antiviral levels in the blood. Storage: Store in the original moisture-proof packaging at room temperature (below 30°C) away from direct sunlight. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that Hepcinat Plus—manufactured by Natco Pharma—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology clinics and “Named Patient“ programs in London and across the UK. United States: Providing affordable access for specialized pharmacy requirements and clinical research. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s leading medical hubs and specialty pharmacies. Australia & South Africa: Reliable bulk supply for public health initiatives and regional medical distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Myhepdvir Tablet: The Definitive Treatment for Chronic Hepatitis B – Global Supply by Ernest Oncology The management of Chronic Hepatitis B (HBV) requires high-potency antiviral therapy to prevent liver complications such as cirrhosis and hepatocellular carcinoma. Myhepdvir, containing Tenofovir Alafenamide (25mg), represents the latest advancement in Nucleotide Reverse Transcriptase Inhibitor (NtRTI) therapy. Designed for superior efficacy with a safer profile for bone and kidney health, Myhepdvir is a cornerstone in modern HBV treatment protocols. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Myhepdvir to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Myhepdvir? (The TAF Advantage) Myhepdvir is a premium generic version of Vemlidy. It utilizes Tenofovir Alafenamide (TAF), a prodrug of Tenofovir. Compared to the older Tenofovir Disoproxil Fumarate (TDF), TAF is more stable in the plasma and delivers the active metabolite more efficiently to the liver cells (hepatocytes). This efficiency allows for a significantly lower dose (25mg vs 300mg), which results in 90% less Tenofovir in the bloodstream, drastically reducing the risk of renal toxicity and bone mineral density loss. Primary Indications & Medical Uses Chronic Hepatitis B Virus (HBV): For the treatment of chronic HBV infection in adults with compensated liver disease. HBeAg-Positive & HBeAg-Negative Patients: Effective across various viral profiles and stages of chronic infection. Long-term Suppression: Designed for long-term use to keep viral loads at undetectable levels and promote ALT (liver enzyme) normalization. Detailed Product Information: Myhepdvir (25mg) Feature, Technical Specification Active Ingredient: Tenofovir Alafenamide (25mg) Therapeutic Class: Nucleotide Reverse Transcriptase Inhibitor (NtRTI) Manufacturers: Mylan (Viatris) / Natco Pharma (India) Form: Film-coated tablets (30 Tablets per bottle) Treatment Type: Long-term antiviral suppression Safety Profile: Superior Renal & Bone Safety (compared to TDF) Quality Standard, GMP Certified Production Mechanism of Action: Target-Specific Inhibition Myhepdvir works by inhibiting the Hepatitis B virus polymerase, an enzyme required for the virus to replicate its DNA. Intracellular Activation: Once ingested, Myhepdvir is converted into Tenofovir diphosphate inside the liver cells. Chain Termination: Tenofovir diphosphate competes with the natural substrate of the viral DNA, incorporating itself into the viral DNA chain and causing immediate termination of replication. Dosage and Administration Standard Regimen: One 25mg tablet taken orally, once daily. Administration: Must be taken with food to ensure optimal absorption. Monitoring: Regular monitoring of liver function (ALT levels) and HBV DNA viral load is recommended to assess treatment response. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that Myhepdvir—manufactured in world-class Indian facilities—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private clinics and specialized hepatology centers in London and across the UK. United States: Providing affordable access for specialized pharmacy requirements and clinical research. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s most advanced medical hubs and specialty clinics. Australia & South Africa: Reliable bulk supply for public health departments and regional medical distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Sofocure V Tablet: The Definitive Pan-Genotypic Cure for Hepatitis C – Global Supply by Ernest Oncology The landscape of Chronic Hepatitis C (HCV) treatment has reached a historic milestone with the development of “pan-genotypic“ therapies. Sofocure V, a high-potency fixed-dose combination of Sofosbuvir (400mg) and Velpatasvir (100mg), represents the gold standard in this evolution. Designed to eliminate the Hepatitis C virus across all six major genotypes, Sofocure V offers a simplified, once-daily oral regimen that achieves unprecedented cure rates. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, WHO-GMP-compliant international distribution of Sofocure V to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Sofocure V? (The Science of Eradication) Sofocure V is a premium generic version of the breakthrough medication Epclusa. It integrates two distinct Direct-Acting Antivirals (DAAs) that work synergistically to stop the virus from replicating and assembling new particles. Unlike traditional therapies of the past, Sofocure V is an all-oral regimen, removing the need for interferon injections and their associated severe side effects. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1–6): A universal treatment for all known HCV genotypes in adults and pediatric patients (3 years and older). Compensated Cirrhosis: Highly effective for patients with early-to-mid-stage liver scarring. Decompensated Cirrhosis: When combined with Ribavirin, it provides a life-saving treatment path for patients with advanced liver disease. HCV/HIV Co-infection: Proven safe for patients managing co-infection, maintaining a stable drug-interaction profile. Detailed Product Information: Sofocure V (400mg/100mg) Feature, Technical Specification Active Ingredients: Sofosbuvir (400mg) + Velpatasvir (100mg) Therapeutic Class: Antiviral (HCV NS5B & NS5A Inhibitor) Manufacturer: Emcure Pharmaceuticals (India) Treatment Duration: Standard 12-Week Course (84 Days) Form: Film-coated tablets (28 Tablets per bottle) Efficacy Rate: >95% Sustained Virologic Response (SVR12) Quality Standard, GMP-Certified Production Mechanism of Action: The Double-Inhibitor Strategy Sofocure V eradicates the virus by attacking two critical phases of its replication cycle: Sofosbuvir (400mg): An NS5B polymerase inhibitor. It acts as a “chain terminator,“ mimicking the building blocks of the virus to halt the replication of viral RNA. Velpatasvir (100mg): An NS5A inhibitor. It blocks the NS5A protein, which the virus essentially requires for both the replication and assembly of new viral particles. Dosage and Administration Standard Regimen: One tablet taken orally once per day. Administration: Can be taken with or without food. However, it is vital to take the tablet at the same time every day to maintain steady blood levels of the medication. Patient Compliance: Completing the full 12-week course is mandatory to prevent viral resistance and ensure a permanent cure. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that Sofocure V—manufactured by Emcure Pharmaceuticals—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology networks and “Named Patient“ programs in London and across the UK. United States: Providing affordable access for specialized pharmacy requirements, clinical research, and hospital procurement. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s most advanced medical hubs and specialty clinics. Australia & South Africa: Reliable bulk supply for public health departments, regional medical distributors, and government tenders. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Resof Total Tablet: The Ultimate Pan-Genotypic Breakthrough for Hepatitis C – Global Supply by Ernest Oncology The medical community has witnessed a paradigm shift in the treatment of Chronic Hepatitis C (HCV). Resof Total, a high-potency fixed-dose combination of Sofosbuvir (400mg) and Velpatasvir (100mg), represents the gold standard in “pan-genotypic“ therapy. This advanced formulation is designed to simplify the cure for all six major genotypes of the virus, offering a reliable pathway to viral eradication with a single daily tablet. Ernest Oncology, the specialized pharmaceutical division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Resof Total to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Resof Total? (The Science of Eradication) Resof Total is a generic version of the breakthrough medication Epclusa. It combines two powerful Direct-Acting Antivirals (DAAs) that work synergistically to stop the Hepatitis C virus from replicating. Unlike older treatments that required interferon injections—which often came with severe side effects—Resof Total is an all-oral regimen with a superior safety profile. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1–6): The first-line choice for adults and pediatric patients (3 years and older) across all genotypes. Patients with Cirrhosis: Highly effective for those with compensated cirrhosis. Advanced Liver Disease: When combined with Ribavirin, it serves as a critical treatment for patients with decompensated cirrhosis. HCV/HIV Co-infection: Proven safe for patients managing both conditions simultaneously. Detailed Product Information: Resof Total (400mg/100mg) Feature, Technical Specification Active Ingredients: Sofosbuvir (400mg) + Velpatasvir (100mg) Drug Class: NS5B Polymerase Inhibitor + NS5A Inhibitor Manufacturer: Dr. Reddy’s Laboratories (India) Form: Film-coated tablets (28 Tablets per bottle) Standard Duration, 12 Weeks (84 Days) Efficacy Rate > 97% Sustained Virologic Response (SVR12) Regulatory Status: Manufactured in GMP Certified Facilities Mechanism of Action: The Dual-Inhibitor Advantage Resof Total attacks the virus at two different stages of its life cycle, making it nearly impossible for the virus to develop resistance: Sofosbuvir (400mg): An NS5B polymerase inhibitor. It mimics the building blocks the virus needs to copy its RNA but acts as a “chain terminator,“ stopping the replication process dead in its tracks. Velpatasvir (100mg): An NS5A inhibitor. It blocks the NS5A protein, which the virus requires for both the replication and assembly of new viral particles. Dosage and Administration Standard Regimen: One tablet taken once daily. Administration: Can be taken with or without food. However, consistency is key—patients should take the dose at the same time every day. Patient Compliance: It is critical to complete the full 12-week course, even if viral loads become undetectable early in the treatment, to ensure a permanent cure. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complexities of international pharmaceutical trade. We ensure that Resof Total—manufactured by Dr. Reddy’s Laboratories—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology networks and named-patient programs in London and across the UK. United States: Providing affordable access for clinical research, specialized pharmacies, and patient advocacy groups. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s most advanced medical diagnostic and treatment hubs. Australia & South Africa: Reliable bulk supply for public health departments, regional distributors, and NGOs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Myhep All Tablet: The Definitive Pan-Genotypic Cure for Hepatitis C – Global Supply by Ernest Oncology The introduction of pan-genotypic Direct-Acting Antivirals (DAAs) has redefined the clinical approach to Chronic Hepatitis C (HCV). Myhep All, a potent fixed-dose combination of Sofosbuvir (400mg) and Velpatasvir (100mg), is at the forefront of this medical revolution. It is specifically engineered to treat all six major genotypes of the Hepatitis C Virus with a simplified, once-daily oral regimen, boasting cure rates that have effectively made HCV a manageable and eradicable disease. Ernest Oncology, the specialized pharmaceutical division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We ensure the secure, verified international distribution of Myhep All to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa through specialized pharmaceutical logistics and cold-chain integrity. What is Myhep All? (The Science of SVR12) Myhep All is a high-quality, generic version of the breakthrough medication Epclusa. By combining two distinct antiviral mechanisms into a single film-coated tablet, Myhep All eliminates the need for painful interferon injections and, for the vast majority of patients, removes the requirement for Ribavirin. Clinical data indicates a Sustained Virologic Response (SVR12)—clinically defined as a cure—in 98% to 100% of patients without cirrhosis or with compensated cirrhosis. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1, 2, 3, 4, 5, & 6): A universal treatment for all known HCV genotypes in adults and pediatric patients (3 years and older). Patients with Cirrhosis: Highly effective for both compensated and, when used in conjunction with Ribavirin, decompensated cirrhosis (advanced liver scarring). HCV/HIV Co-infection: Safe and effective for patients managing both Hepatitis C and HIV-1, with minimal drug-drug interactions. Detailed Product Information: Myhep All (400mg/100mg) Feature, Technical Specification Active Ingredients: Sofosbuvir (400mg) + Velpatasvir (100mg) Therapeutic Class: NS5B Polymerase Inhibitor + NS5A Inhibitor Manufacturers: Mylan (Viatris) / Natco Pharma (India) Form: Film-coated tablets (28 Tablets per bottle) Treatment Duration: Standard 12-week course (84 days) Success Rate: >95% Sustained Virologic Response (SVR) Regulatory Standards, GMP & ISO Certified Manufacturing Mechanism of Action: The Dual-Blockade System Myhep All works by stopping the virus from replicating at two critical stages of its lifecycle: Sofosbuvir (400mg): This is an NS5B RNA-dependent RNA polymerase inhibitor. It acts as a “defective building block“ that terminates the viral RNA chain during replication, effectively stopping the virus from copying its genetic material. Velpatasvir (100mg): This targets the NS5A protein, which is essential for both the replication of the virus and the assembly of new viral particles. By blocking this protein, the virus cannot spread to healthy liver cells. Dosage and Administration Standard Regimen: One tablet taken once daily for a duration of 12 weeks. Administration: The tablet can be taken with or without food. It is vital to take the dose at the same time every day to maintain steady blood concentrations and prevent viral rebound. Storage: Store in the original moisture-proof packaging at room temperature (below 30°C) away from direct sunlight. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in the global transit of life-saving specialty medicines. We navigate the complex regulatory environments of international pharmaceutical trade to ensure that Myhep All reaches patients and healthcare providers through legal and compliant trade channels. United Kingdom & London: Supporting private hepatology clinics and specialized “Named Patient“ programs throughout the UK. United States: Providing cost-effective access for specialized pharmacy requirements, clinical research, and hospital procurement. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s most advanced medical hubs and specialty pharmacies. Australia & South Africa: Reliable bulk supply for public health initiatives, regional medical distributors, and government tenders. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Velakast Tablet: The Advanced Pan-Genotypic Cure for Hepatitis C – Global Supply by Ernest Oncology In the field of viral hepatology, the development of fixed-dose combinations has transformed Hepatitis C from a chronic, life-threatening condition into a curable one. Velakast, a powerful combination of Sofosbuvir ($400text{mg}$) and Velpatasvir ($100text{mg}$), is a “pan-genotypic“ medication, meaning it is clinically proven to treat all six major genotypes (1–6) of the Hepatitis C Virus (HCV). Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure international distribution of Velakast to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical export channels. What is Velakast? Velakast is a high-quality generic version of the breakthrough drug Epclusa. It is a complete, once-daily oral regimen that eliminates the need for interferon injections. By targeting the virus's ability to replicate, Velakast achieves a cure rate (Sustained Virologic Response) of over 95% across various patient populations. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1-6): The primary treatment for adults and pediatric patients (aged 3 and older). Compensated Cirrhosis: Effective for patients with early-to-mid-stage liver scarring. Decompensated Cirrhosis: When used alongside Ribavirin, Velakast provides a vital treatment path for patients with advanced liver disease. Detailed Product Information: Velakast ($400text{mg}$/$100text{mg}$) Feature,Technical Specification Active Ingredients: Sofosbuvir (400mg) + Velpatasvir (100mg) Drug Class: Direct-Acting Antivirals (DAAs) Manufacturer: Aprazer Healthcare / Natco Pharma (India) Form: Film-coated tablets (28 Tablets per bottle) Treatment Cycle, 12 Weeks (Standard) Quality Standard, GMP-Certified Production Mechanism of Action: The Dual-Inhibitor Advantage Velakast uses two specialized mechanisms to eradicate the virus:Sofosbuvir ($400text{mg}$): An NS5B polymerase inhibitor. It prevents the virus from copying its genetic material (RNA), effectively stopping the virus from reproducing.Velpatasvir ($100text{mg}$): An NS5A inhibitor. It blocks a protein necessary for both the replication and assembly of new virus particles. Dosage and Administration Standard Dose: One tablet taken once daily for a duration of 12 weeks. Administration: The tablet can be taken with or without food. It is essential to maintain a consistent daily schedule to ensure maximum efficacy. Patient Compliance: Completing the full 12-week course is mandatory to prevent viral resistance, even if the patient feels significantly better early in the treatment. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in the logistics of life-critical specialty medicines. We ensure that Velakast reaches international healthcare networks through verified legal pathways and strict cold-chain management where necessary. United Kingdom & London: Supporting private hepatology clinics and named-patient programs throughout the UK. United States: Providing affordable access for specialized pharmacy requirements and clinical research. Abu Dhabi & UAE: Fast-track export to the Middle East’s leading medical hubs and diagnostic centers. Australia & South Africa: Reliable bulk supply for public health departments, regional distributors, and NGOs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in international antiviral and oncology medicine supply. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Velasof Tablet: The Definitive Pan-Genotypic Cure for Hepatitis C – Global Supply by Ernest Oncology The landscape of Hepatitis C (HCV) treatment has been revolutionized by the introduction of highly effective Direct-Acting Antivirals (DAAs). Velasof, a potent fixed-dose combination of Sofosbuvir (400mg) and Velpatasvir (100mg), stands at the forefront of this medical breakthrough. As a “pan-genotypic“ therapy, it is engineered to treat all six major genotypes of the virus with a single daily tablet. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We ensure the secure, temperature-controlled international distribution of Velasof to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistical channels. What is Velasof? Velasof is an authorized generic version of the breakthrough medication Epclusa. It is a complete oral regimen that eliminates the need for interferon injections and, in many cases, avoids the use of Ribavirin. By inhibiting the proteins essential for viral replication, Velasof can achieve a Sustained Virologic Response (SVR12)—clinically defined as a cure—in over 95% to 99% of patients. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1, 2, 3, 4, 5, & 6): The primary choice for adults and pediatric patients (3 years and older) with any HCV genotype. Compensated Cirrhosis: Highly effective for patients with early-stage liver scarring. Decompensated Cirrhosis: When prescribed with Ribavirin, Velasof is a life-saving option for patients with advanced liver disease. Detailed Product Information: Velasof (Sofosbuvir/Velpatasvir) Feature,Technical Specification Active Ingredients,Sofosbuvir (400mg) + Velpatasvir (100mg) Therapeutic Class,Antiviral (HCV NS5B & NS5A Inhibitor) Manufacturer,Hetero Healthcare / Hetero Labs (India) Treatment Duration,12 Weeks (Standard Course) Form,Film-coated tablets (28 Tablets per pack) Quality Standard,WHO-GMP Certified Manufacturing Mechanism of Action: The Dual-Inhibitor Strategy Velasof utilizes two distinct pathways to eradicate the Hepatitis C virus: Sofosbuvir (400mg): An NS5B polymerase inhibitor. It acts as a “chain terminator,“ preventing the virus from copying its genetic material (RNA). Velpatasvir (100mg): An NS5A inhibitor. It blocks a specific protein that the virus requires for both replication and the assembly of new viral particles. Dosage and Administration Standard Regimen: One tablet taken orally, once daily, for 12 consecutive weeks. Administration: Can be taken with or without food. Consistency is critical; missing doses can reduce the effectiveness of the treatment. Storage: Store in a cool, dry place away from direct sunlight at temperatures below 30°C. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology specializes in navigating the complex regulatory environments of international pharmaceutical trade. We ensure that Velasof—manufactured by Hetero Labs under stringent global standards—is accessible to healthcare providers and patients worldwide. United Kingdom & London: Supporting private hepatology clinics and named-patient programs across the UK. United States: Providing cost-effective access for specialized clinical research and patient advocacy groups. Abu Dhabi & UAE: Fast-tracked export for the Middle East’s premier medical hubs and specialty pharmacies. Australia & South Africa: Reliable bulk supply for public health initiatives, regional distributors, and hospital tenders. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of oncology and antiviral medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Telura Tablet: The Triple-Combination Breakthrough in HIV-1 Management – Global Supply by Ernest Oncology In the ongoing global effort to manage HIV effectively, Telura stands as a cornerstone of modern Antiretroviral Therapy (ART). As a fixed-dose combination of Tenofovir Disoproxil Fumarate ($300text{mg}$), Lamivudine ($300text{mg}$), and Efavirenz ($600text{mg}$), it simplifies complex treatment schedules into a single, high-efficacy daily pill. What is Telura? Telura is a complete, once-daily regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least $40text{kg}$. It is widely recognized for its clinical reliability and is often used as a first-line treatment in various international health protocols. Primary Indications & Medical Uses HIV-1 Infection Treatment: Used to reduce the viral load to undetectable levels, thereby strengthening the immune system. Long-term Maintenance: Provides a stable, long-term solution for patients who are stable on this specific ART combination. Prevention of Transmission: By suppressing the virus, it significantly reduces the risk of transmitting HIV to others (U=U principle). Detailed Product Information: Telura (TDF/3TC/EFV) Feature,Technical Specification Active Ingredients,Tenofovir Disoproxil Fumarate (300mg) + Lamivudine (300mg) + Efavirenz (600mg) Drug Class,NRTI + NtRTI + NNRTI Combination Manufacturer,Mylan (A Viatris Company) / Hetero Labs (India) Form,Film-coated tablets (30 tablets per bottle) Mechanism,Triple-action viral replication inhibition Telura Tablet: The Triple-Combination Breakthrough in HIV-1 Management – Global Supply by Ernest Oncology In the ongoing global effort to manage HIV effectively, Telura stands as a cornerstone of modern Antiretroviral Therapy (ART). As a fixed-dose combination of Tenofovir Disoproxil Fumarate (300mg), Lamivudine (300mg), and Efavirenz (600mg), it simplifies complex treatment schedules into a single, high-efficacy daily pill. Ernest Oncology, the specialized pharmaceutical division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure international distribution of Telura to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical export channels. What is Telura? Telura is a complete, once-daily regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40kg. It is widely recognized for its clinical reliability and is often used as a first-line treatment in various international health protocols. Primary Indications & Medical Uses HIV-1 Infection Treatment: Used to reduce the viral load to undetectable levels, thereby strengthening the immune system. Long-term Maintenance: Provides a stable, long-term solution for patients who are stable on this specific ART combination. Prevention of Transmission: By suppressing the virus, it significantly reduces the risk of transmitting HIV to others (U=U principle). Detailed Product Information: Telura (TDF/3TC/EFV) Feature Technical Specification Active Ingredients Tenofovir Disoproxil Fumarate (300mg) + Lamivudine (300mg) + Efavirenz (600mg) Drug Class NRTI + NtRTI + NNRTI Combination Manufacturer Mylan (A Viatris Company) / Hetero Labs (India) Form Film-coated tablets (30 tablets per bottle) Mechanism Triple-action viral replication inhibition Mechanism of Action: How it Works Telura attacks the virus using two distinct classes of antiretrovirals: Tenofovir (300mg) & Lamivudine (300mg): These are Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs). They block the reverse transcriptase enzyme, preventing the virus from converting its RNA into DNA. Efavirenz (600mg): A Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) that binds directly to the enzyme to stop it from working. Dosage and Administration Standard Dose: One tablet taken once daily. Administration: It is highly recommended to take Telura on an empty stomach, preferably at bedtime. This helps reduce the severity of potential side effects associated with Efavirenz, such as dizziness or vivid dreams. Consistency: To ensure maximum effectiveness, the tablet should be taken at the same time every day to maintain a steady concentration in the bloodstream. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in international antiviral and oncology medicine supply. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383